Methods for Identifying Candidate Therapeutics for Antibody-Mediated Inflammatory Demyelinating Disease Using Single-Cell RNA Sequencing of Cerebrospinal Fluid and Transcriptomic Reversal Scoring — Provisional Patent Specification
Fuente:
Zenodo
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901968960618496 |
|---|---|
| author | Ritschel, Glen Charles Claude |
| author_facet | Ritschel, Glen Charles Claude |
| contents | <p>Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in antibody-mediated inflammatory demyelinating disease (Ab-IDD), encompassing NMOSD and MOGAD, using single-cell RNA sequencing of cerebrospinal fluid from 6 Ab-IDD patients, 3 MS patients, and 2 healthy controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering (27 clusters), three-way Wilcoxon differential expression (Ab-IDD vs Normal, MS vs Normal, Ab-IDD vs MS) with ASDC, B cell, and pro-Ab-IDD cluster subset analyses, and LINCS L1000 transcriptomic reversal scoring. Application to GSE194078 across 29 independent Enrichr queries identified 374 NOVEL_ALL candidates (69% of assessed compounds). Top candidates: SAR405838 (MDM2 inhibitor, priority 635,155), R-547 (CDK inhibitor, 600,699), RG-7388 (MDM2 inhibitor, 494,007), AMG-232 (MDM2 inhibitor, 461,017), TAK-733 (MEK1/2 inhibitor, 205,471), MRE-269 (prostacyclin agonist), LXR-623 (LXR agonist). Six MDM2 inhibitors in the top 20 extend cross-disease p53-MDM2 axis findings to five independent tissues. R-547 achieves five-pipeline NOVEL_ALL consistency. The three-way disease comparison design captures Ab-IDD-specific transcriptomic contrast unavailable from binary comparisons. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19154134 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Methods for Identifying Candidate Therapeutics for Antibody-Mediated Inflammatory Demyelinating Disease Using Single-Cell RNA Sequencing of Cerebrospinal Fluid and Transcriptomic Reversal Scoring — Provisional Patent Specification Ritschel, Glen Charles Claude provisional patent NMOSD neuromyelitis optica MOGAD MOG antibody Ab-IDD cerebrospinal fluid scRNA-seq drug repurposing LINCS L1000 MDM2 inhibitor SAR405838 R-547 RG-7388 AMG-232 TAK-733 MEK LXR-623 ASDC AXL SIGLEC6 AQP4 complement GSE194078 scVI USPTO micro-entity <p>Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in antibody-mediated inflammatory demyelinating disease (Ab-IDD), encompassing NMOSD and MOGAD, using single-cell RNA sequencing of cerebrospinal fluid from 6 Ab-IDD patients, 3 MS patients, and 2 healthy controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering (27 clusters), three-way Wilcoxon differential expression (Ab-IDD vs Normal, MS vs Normal, Ab-IDD vs MS) with ASDC, B cell, and pro-Ab-IDD cluster subset analyses, and LINCS L1000 transcriptomic reversal scoring. Application to GSE194078 across 29 independent Enrichr queries identified 374 NOVEL_ALL candidates (69% of assessed compounds). Top candidates: SAR405838 (MDM2 inhibitor, priority 635,155), R-547 (CDK inhibitor, 600,699), RG-7388 (MDM2 inhibitor, 494,007), AMG-232 (MDM2 inhibitor, 461,017), TAK-733 (MEK1/2 inhibitor, 205,471), MRE-269 (prostacyclin agonist), LXR-623 (LXR agonist). Six MDM2 inhibitors in the top 20 extend cross-disease p53-MDM2 axis findings to five independent tissues. R-547 achieves five-pipeline NOVEL_ALL consistency. The three-way disease comparison design captures Ab-IDD-specific transcriptomic contrast unavailable from binary comparisons. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.</p> |
| title | Methods for Identifying Candidate Therapeutics for Antibody-Mediated Inflammatory Demyelinating Disease Using Single-Cell RNA Sequencing of Cerebrospinal Fluid and Transcriptomic Reversal Scoring — Provisional Patent Specification |
| topic | provisional patent NMOSD neuromyelitis optica MOGAD MOG antibody Ab-IDD cerebrospinal fluid scRNA-seq drug repurposing LINCS L1000 MDM2 inhibitor SAR405838 R-547 RG-7388 AMG-232 TAK-733 MEK LXR-623 ASDC AXL SIGLEC6 AQP4 complement GSE194078 scVI USPTO micro-entity |
| url | https://doi.org/10.5281/zenodo.19154134 |